Author:
Treewattanawong Wantanee,Sitthiyotha Thassanai,Chunsrivirot Surasak
Abstract
AbstractDuring the COVID-19 pandemic, SARS-CoV-2 has caused large numbers of morbidity and mortality, and the Omicron variant (B.1.1.529) was an important variant of concern. To enter human cells, the receptor-binding domain (RBD) of the S1 subunit of SARS-CoV-2 (SARS-CoV-2-RBD) binds to the peptidase domain (PD) of Angiotensin-converting enzyme 2 (ACE2) receptor. Disrupting the binding interactions between SARS-CoV-2-RBD and ACE2-PD using neutralizing antibodies is an effective COVID-19 therapeutic solution. Previous study found that Beta-27 Fab, which was obtained by digesting the full IgG antibodies that were isolated from a patient infected with SARS-CoV-2 Beta variant, can neutralize Victoria, Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2) variants. This study employed computational protein design and molecular dynamics (MD) to investigate and enhance the binding affinity of Beta-27 Fab to SARS-CoV-2-RBD Omicron variant. MD results show that five best designed Beta-27 Fabs (Beta-27-D01 Fab, Beta-27-D03 Fab, Beta-27-D06 Fab, Beta-27-D09 Fab and Beta-27-D10 Fab) were predicted to bind to Omicron RBD in the area, where ACE2 binds, with significantly better binding affinities than Beta-27 Fab and ACE2. Their enhanced binding affinities are mostly caused by increased binding interactions of CDR L2 and L3. They are promising candidates that could potentially be employed to disrupt the binding between ACE2 and Omicron RBD.
Funder
The Structural and Computational Biology Research Unit, Department of Biochemistry, Faculty of Science, Rachadaphiseksomphot Endowment Fund, Chulalongkorn University, Thailand.
Publisher
Springer Science and Business Media LLC
Reference82 articles.
1. Matheson, N. J. & Lehner, P. J. How does SARS-CoV-2 cause COVID-19?. Science 369, 510–511 (2020).
2. Hui, D. S. et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China. Int. J. Infect. Dis. 91, 264–266 (2020).
3. Adem, K. A., Shanti, A., Stefanini, C. & Lee, S. Inhibition of SARS-CoV-2 entry into host cells using small molecules. Pharmaceuticals 13, 447 (2020).
4. Huang, X., Pearce, R. & Zhang, Y. D. De novo design of protein peptides to block association of the SARS-CoV-2 spike protein with human ACE2. Aging 12, 11263–11276 (2020).
5. Kar, S. & Leszczynski, J. From animal to human: Interspecies Analysis provides a novel way of ascertaining and fighting COVID-19. The Innovation 1, 100021 (2020).